RxDoctor Payments DataLook up a doctor →

Dana Grosch

Family · Columbia, ILNPI 1447651708

Payments from drug & device makers

$15,661in general payments, 2019–2025

Across 880 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • Lilly USA, LLC$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$818
  • Novo Nordisk$756
  • plus $7K from 52 others

What the payments were for

  • Food & beverage$15,49499%
  • Education$1671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie165$2,553
AstraZeneca80$1,809
Johnson & Johnson95$1,764
Lilly USA, LLC62$1,026
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)41$818
Novo Nordisk44$756
Otsuka America Pharmaceutical, Inc.25$485
Boehringer Ingelheim26$446
Pfizer38$422
Amgen20$356
Lundbeck LLC15$311
Alkermes, Inc.12$310
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC21$309
GSK17$295
Axsome Therapeutics, Inc.11$283
Bayer17$277
Sumitomo Pharma America, Inc.12$252
Tris Pharma Inc13$235
Neos Therapeutics, LP15$230
Merck10$210
Astellas Pharma US Inc7$204
Antares Pharma, Inc.9$199
Takeda Pharmaceuticals U.S.A., Inc.9$188
Biohaven Pharmaceuticals, Inc.19$186
Azurity Pharmaceuticals, Inc.11$161
Exact Sciences8$156
Kowa Pharmaceuticals America, Inc.9$128
Novartis6$106
Paratek Pharmaceuticals, Inc.7$103
Biohaven Pharmaceutical Holding Company Ltd.5$92
Nestle Healthcare Nutrition Inc.4$82
Dexcom, Inc.4$73
Impel Pharmaceuticals Inc.3$72
Idorsia Pharmaceuticals US Inc3$65
Amarin Pharma, Inc.3$63
Sunovion Pharmaceuticals Inc.4$62
Neurocrine Biosciences, Inc.3$58
Acerus Pharmaceuticals Corporation3$53
Halozyme Inc2$44
Verity Pharmaceuticals Inc.2$44
Vanda Pharmaceuticals Inc.1$35
Insulet Corporation1$32
Almatica Pharma LLC2$29
Edwards Lifesciences1$29
E.r. Squibb & Sons, L.L.C.1$28
Ironshore Pharmaceuticals Inc.1$22
Hikma Pharmaceuticals USA1$21
Clarus Therapeutics Inc.1$20
Corcept Therapeutics1$20
Shield Therapeutics Inc1$19
Aytu Biopharma, Inc.1$18
Abbott1$18
Supernus Pharmaceuticals, Inc.1$15
Eisai Inc.1$15
Phathom Pharmaceuticals, Inc.1$14
Esperion Therapeutics, Inc.1$14
Electromed, Inc.2$13
Arbor Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,661 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$53,141
Medicare patients
216
Services billed
1,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$160,997
MounjaroTirzepatide106$122,666
FarxigaDapagliflozin Propanediol77$58,342
RexultiBrexpiprazole34$51,179
XareltoRivaroxaban56$50,038
JardianceEmpagliflozin43$43,806
TrulicityDulaglutide19$35,078
RybelsusSemaglutide19$32,000
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$25,431
EliquisApixaban26$22,938
LinzessLinaclotide23$20,657
Breo ElliptaFluticasone/Vilanterol12$10,123
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$6,919
Tresiba Flextouch U-100Insulin Degludec11$6,822
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen253$6,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$756$192,997161 claims
Lilly USA, LLCMounjaro, Trulicity$1,026$157,744125 claims
AstraZenecaFarxiga$1,809$58,34277 claims
Otsuka America Pharmaceutical, Inc.Rexulti$485$51,17934 claims
Johnson & JohnsonXarelto$1,764$50,03856 claims
Boehringer IngelheimJardiance$446$43,80643 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$295$42,47350 claims
PfizerEliquis$422$22,93826 claims
AbbVieLinzess$2,553$20,65723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Columbia

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →